MétaCan
Menu
← Back to cohort
Record W4414930819 · doi:10.1038/s41467-025-64042-5

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

2025· article· en· W4414930819 on OpenAlexaff
Juan M. Jiménez-Vacas, Daniel Westaby, Ines Figueiredo, Alexis de Haven Brandon, Ana Padilha, Wei Yuan, George Seed, Denisa Bogdan, Bora Gürel, Claudia Bertan, Susana Miranda, Maryou B. Lambros, Antonio J. Montero‐Hidalgo, Ilsa M. Coleman, Ivan Pak Lok Yu, Lorenzo Buroni, Wanting Zeng, Antje Neeb, Jon Welti, Jan Rekowski, Roberta Paravati, Florian Gabel, Nicole Pandell, Ana Ferreira, Mateus Crespo, Ruth Riisnaes, Souvik Das, John D. Taylor, Nick Waldron, Emily Hobern, Melanie Valenti, Jian Ning, Ilona Bernett, Kate Liodaki, Thomas Persse, Patricia C. Galipeau, Scott Wilkinson, Shana Y. Trostel, Fatima Karzai, Cindy H. Chau, Erica L. Beatson, Xiaohu Zhang, Carleen Klumpp‐Thomas, Andreas Varkaris, Raúl M. Luque, Amanda Swain, Florence I. Raynaud, Nathan A. Lack, Craig J. Thomas, Gavin Ha, William D. Figg, Marco Bezzi, Adam G. Sowalsky, Peter S. Nelson, Suzanne Carreira, Steven P. Balk, Johann S. de Bono, Adam Sharp

Bibliographic record

VenueNature Communications · 2025
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsUniversity of British Columbia
FundersNational Cancer InstituteMedical Research CouncilRoyal Society of MedicineProstate Cancer UKNational Institute for Health and Care ResearchGovernment of the United KingdomNational Center for Advancing Translational SciencesWellcome TrustInstitute for Prostate Cancer ResearchAmerican Association for Cancer ResearchProstate Cancer FoundationMovember FoundationWellcomeUniversity of WashingtonCancer Research UKNational Institutes of HealthU.S. Department of Health and Human Services
KeywordsMCL1Prostate cancerProtein kinase BDownregulation and upregulationPI3K/AKT/mTOR pathwayCancer

Abstract

fetched live from OpenAlex

Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease requiring additional therapeutic strategies. MCL1, an anti-apoptotic BCL2 family member, promotes cancer-cell survival, but its role in mCRPC remains poorly understood. Here, we characterise MCL1 in multiple mCRPC biopsy cohorts and patient-derived models, assessing responses to MCL1 inhibition. MCL1 copy number gain (14%-34%) correlates with increased MCL1 expression and worse outcomes. MCL1 inhibition exhibits anti-tumour effects in MCL1-gained mCRPC models. Co-inhibition of MCL1 and AKT induces cancer-specific cell death in PTEN-loss/PI3K-activated models in vitro and in vivo, modulating BAD-BCLXL and BIM-MCL1 interactions, with durable anti-tumour activity in models with AKT inhibitor acquired resistance. Finally, CDK9-mediated MCL1 downregulation combined with AKT inhibition recapitulates these findings, providing further opportunities for clinical translation. These data support early phase clinical trials targeting MCL1, both as monotherapy for MCL1-gained mCRPC, and in combination with AKT inhibition for PTEN-loss/PI3K-activated mCRPC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.392
Teacher spread0.350 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNature Communications→Same topicProstate Cancer Treatment and Research→French-language works237,207→